News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trinean nv Secures $1 Million Euro Financing



6/6/2013 9:24:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ghent, Belgium – May 30, 2013 - Trinean, the leading provider of microfluidic spectrophotometry platforms, announced today to have secured a 1 million euro investment in a second closing of its 3.7 million fundraising round. The investment is done by Capricorn Health-tech Fund NV (Leuven, Belgium) which is managed by Capricorn Venture Partners NV.

Dr. Gaston Matthyssens, Trinean’s president, comments on today’s announcement: “Over the past 24 months, Trinean has proven to be able to attract substantial funding to boost its market and sales strategy, and to bring novel, state-of-the-art instruments to the market. Most recently, we have launched the Xpose®, our new micro-volume spectrophotometer for high speed quantification of nucleic acid or proteins samples”.

Dr. Frank Bulens, Partner at Capricorn Venture Partners, will join Trinean’s board of directors. “We are very pleased to enforce the existing investor syndicate of Trinean and are looking forward to assist the company in reaching its next phase of development, namely to become a successful player in the micro-volume spectroscopy market,” comments Frank Bulens, “In our view Trinean will achieve that goal based on a superior product offering supported by a seasoned management team.”

“We are delighted to welcome Capricorn Health-tech Fund to our investor syndicate,” says Philippe Stas, CEO Trinean, “This will allow Trinean to accelerate its application-driven expansion of the DropSense96® and Xpose® product lines and to extend our production facilities, matching the increasing demand for instruments and microfluidic solutions.”

About Trinean

Trinean is a Belgium based instrumentation company, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform.

Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes two instruments, the Xpose® for ‘Touch & Go’ biomolecule quantification and the DropSense96®, analyzing up to 96 samples, using microfluidic chips for standardized sample analysis (DropPlates and Xpose Slides). The Trinean platform is complemented with a software toolbox (including DropControl, DropQuant, cDrop™) for improved data interpretation and lab-automation.

For more information about Trinean, visit http://www.trinean.com.

About Capricorn Venture Partners

Capricorn Venture Partners is an independent pan-European venture capital and asset manager seeking to invest in technology based growth companies. Capricorn’s dedicated investment teams are composed of experienced investment professionals with deep technology expertise and a broad industrial experience. Capricorn is investing out of its Capricorn Health-tech, its Fund Capricorn Cleantech Fund, the Capricorn ICT Arkiv and is managing Quest for Growth, a cross-over fund quoted on EuroNext Brussels, and the Quest Management Cleantech Sicav.

For more information, visit http://www.capricorn.be.

Further information:

Trinean N.V.

ir. Philippe Stas

Chief Executive Officer

Dulle Grietlaan 17/3

B-9050 Gent – Belgium

Tel.: +32-9-272.75.35

Fax.: +32-9-272.75.39

info@trinean.com

Capricorn Venture Partners NV.

Dr. Jos B. Peeters

Managing Director

Lei 19/1

B-3000 Leuven – Belgium

Tel.: +32-16-28.41.00

Fax.: +32-16-28.41.08

jos@capricorn.be


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES